

I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on July 7, 2008.

Frank C. Eisenschenk
Frank C. Eisenschenk, Ph.D., Patent Attorney

SUBMISSION OF SEQUENCE LISTING
UNDER 37 CFR §§1.821-1.825

Patent Application
Docket No. ARS-123
Serial No. 10/573,726

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1614
Applicants : Amanda Proudfoot, Jeffrey Shaw
Serial No. : 10/573,726
Filed : March 28, 2007
Conf. No. : 2240
For : Novel CXCL8 Antagonists

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

SUBMISSION OF SEQUENCE LISTING UNDER 37 CFR §§1.821-1.825


Sir:

Transmitted herewith is a replacement Sequence Listing Under 37 CFR §§1.821 through 1.825 for the above-identified patent application. A Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures was received from the Patent and Trademark Office. Also enclosed is an Amendment Under 37 CFR §1.825(a) through (c).

The Sequence Listing is submitted in computer readable format and on paper. I hereby certify that the paper and computer readable copies contain the same information and that no new material is added by this submission.

The Commissioner is hereby authorized to charge any fees under 37 CFR 1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/sl

Enclosure: Sequence listing in computer readable format